South Korea-based Samsung Biologics (207940.KS) has signed a strategic partnership with Kanaph Therapeutics, it was reported on Wednesday.

The contract has been signed to develop KNP-301, a bi-specific Fc fusion protein intended to treat retinal diseases.

According to Kanaph Therapeutics, the product is aimed at autoimmune diseases by inhibiting the alternative pathway of the complement system. According to the contract, Samsung Biologics is to offer a complete scope of its CDO services from cell line development, process development, non-clinical and clinical material manufacturing to IND submission.